However, the combination of crizotinib with the EGFRi afatinib results in synergistic effects not only in chordoma cells resistant to EGFR inhibition, as reported previously for U-CH2 [9], but also in chordoma cells that respond to EGFRis. The gene discussed is EGFR; the disease is chordoma.